Generics BulletinTeva will have to wait more than a decade to launch its proposed generic version of Amicus Therapeutics’ ultra-rare genetic disorder treatment Galafold (migalastat) 123mg capsules, after reaching a se
ScripThe world of mid-cap biotech is no stranger to share price volatility, but a handful of companies have enjoyed the upside, emerging as rising stars this year thanks to eye-catching early results. A re
Pink SheetThe US first-approver advantage over the European Union remains stark, with eight of ten novel agents first cleared by the US Food and Drug Administration, according to a Pink Sheet analysis of rece
Pink SheetState policy and patient advocacy work will become more prominent in relatively new CEO John Crowley's restructured Biotechnology Innovation Organization. Crowley, who took over as CEO in March, descr